CombiMatrix said that it had record prenatal microarray volume of 1,126 tests in the fourth quarter.
NanoString CEO Brad Gray said on a conference call that oncology was once a primary driver of new instrument placements.
The firm said that it placed 38 XT-8 analyzers in Q4, bringing the total installed base of the instrument to 540 as of the end of 2014.
The firm is also positioning MassArray as a complementary technology to NGS, and hopes to tap into the LDT and liquid biopsy arenas.
The molecular diagnostics firm offered more than 3.2 million shares of its stock at $2.80 per share as part of the offering.
In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.
Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.
The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.
The House of Lords in the UK approves a bill to allow mitochondrial donation.